Company news
Prothena Corporation Plc (NASDAQ:PRTA) news
Every Prothena Corporation Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
August 6, 2026
Prothena to Report Second Quarter 2026 Financial Results on August 6
July 30, 2026
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Prothena to Report First Quarter 2026 Financial Results on May 7
April 30, 2026
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomy...
April 27, 2026
Prothena Announces Leadership Team Updates
April 10, 2026
Prothena : Director's Report and Financial Statements for Fiscal Year 2025
March 27, 2026
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
March 21, 2026
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for ...
March 9, 2026
Prothena Announces up to $100 Million Share Repurchase Plan
February 27, 2026
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
February 19, 2026
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
February 12, 2026
Prothena Announces Board of Directors Update
December 12, 2025
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
November 19, 2025
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
November 11, 2025
Prothena : Reports Third Quarter 2025 Financial Results and Business Highlights
November 8, 2025
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
November 6, 2025
Prothena to Report Third Quarter 2025 Financial Results on November 6
October 30, 2025
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Target...
October 1, 2025
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 28, 2025
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
August 27, 2025
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomy...
August 6, 2025
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
August 4, 2025
Prothena to Report Second Quarter 2025 Financial Results on August 4
July 28, 2025
Prothena Announces Corporate Restructuring
June 18, 2025
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
June 16, 2025
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
May 23, 2025
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
May 8, 2025
Prothena to Report First Quarter 2025 Financial Results on May 8
May 1, 2025
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
February 20, 2025
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
August 8, 2024
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Resea...
May 28, 2024
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
May 8, 2024
Prothena to Report First Quarter 2024 Financial Results on May 8
May 1, 2024
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
April 15, 2024
Prothena Appoints David Ford to Newly Created Chief People Officer Position
March 4, 2024
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
February 21, 2024
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
February 15, 2024
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
February 8, 2024
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
January 8, 2024
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
November 2, 2023
Prothena to Report Third Quarter 2023 Financial Results on November 2
October 26, 2023
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
August 3, 2023
Prothena to Report Second Quarter 2023 Financial Results on August 3
July 27, 2023
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
July 10, 2023
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amy...
June 27, 2023
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
May 16, 2023
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
May 4, 2023